Abolhassani, Hassan
Landegren, Nils
Bastard, Paul
Materna, Marie
Modaresi, Mohammadreza
Du, Likun
Aranda-Guillén, Maribel
Sardh, Fabian
Zuo, Fanglei
Zhang, Peng
Marcotte, Harold
Marr, Nico
Khan, Taushif
Ata, Manar
Al-Ali, Fatima
Pescarmona, Remi
Belot, Alexandre
Béziat, Vivien
Zhang, Qian
Casanova, Jean-Laurent
Kämpe, Olle
Zhang, Shen-Ying
Hammarström, Lennart
Pan-Hammarström, Qiang http://orcid.org/0000-0003-1990-8804
Funding for this research was provided by:
H2020 European Institute of Innovation and Technology (ATAC, 101003650)
National Institutes of Health (R01AI088364)
Karolinska Institute
Article History
Received: 16 September 2021
Accepted: 16 January 2022
First Online: 28 January 2022
Declarations
:
: All the clinical evaluations and experiments were performed according to the guidelines provided by the Ethical Committee at the Tehran University of Medical Sciences.
: Written informed consent for participation to this study was obtained from the patients and/or their parents.
: Written informed consent for publishing the results of this study considering ethical confidentiality and anonymity was obtained from the parents.
: J.L.C. reports being an inventor on patent application PCT/US2021/042741, filed 22 July 2021, submitted by The Rockefeller University, which covers the diagnosis of, susceptibility to, and treatment of viral disease and viral vaccines, including COVID-19 and vaccine-associated diseases. The other authors have no conflicts of interest to report.